



# zymeworks

## Zymeworks to Present at Upcoming Investor Conferences

November 8, 2021

VANCOUVER, British Columbia--(BUSINESS WIRE)--Nov. 8, 2021-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will participate in three upcoming investor conferences.

- Stifel 2021 Virtual Healthcare Conference, November 16<sup>th</sup> – 17<sup>th</sup>. Zymeworks is participating in a fireside chat on November 17<sup>th</sup> at 1:20 p.m. ET.
- Jefferies London Healthcare Conference, November 18<sup>th</sup> – 19<sup>th</sup>. Zymeworks' pre-recorded presentation will be available on the Zymeworks' website listed below on November 18<sup>th</sup>.
- Evercore ISI 4<sup>th</sup> Annual HEALTHCONx Virtual Conference, November 30<sup>th</sup> – December 1<sup>st</sup>. Zymeworks is participating in a fireside chat on November 30<sup>th</sup> at 3:05 p.m. ET.

The Stifel and Evercore fireside chats will be webcast live and available for replay on Zymeworks' website at <http://ir.zymeworks.com/events-and-presentations>.

### About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks' suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks' lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody which is currently enrolling in two pivotal clinical trials, one for HER2-positive gastroesophageal adenocarcinoma (HERIZON-GEA-01) and one for refractory HER2-amplified biliary tract cancer (HERIZON-BTC-01) for which it has been granted Breakthrough Therapy designation by the FDA. Zanidatamab is also being evaluated in several Phase 2 clinical trials for HER2-expressing gastroesophageal, colorectal, and breast cancers. Zymeworks' second clinical candidate, ZW49, is a novel bispecific HER2-targeting antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks' proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies. For additional information about Zymeworks, visit [www.zymeworks.com](http://www.zymeworks.com) and follow [@ZymeworksInc](https://twitter.com/ZymeworksInc) on Twitter.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20211108006065/en/): <https://www.businesswire.com/news/home/20211108006065/en/>

Investor Inquiries:  
Ryan Dercho, Ph.D.  
(604) 678-1388  
[ir@zymeworks.com](mailto:ir@zymeworks.com)

Jack Spinks  
(604) 678-1388  
[ir@zymeworks.com](mailto:ir@zymeworks.com)

Media Inquiries:  
Mary Klem  
(604) 678-1388  
[media@zymeworks.com](mailto:media@zymeworks.com)

Source: Zymeworks Inc.